Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 13Leukemia 4Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Congenital Abnormalities 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm, Residual 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Burkitt Lymphoma 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 3Cytarabine 3zosuquidar trihydrochloride 2Immunotherapy, Adoptive 2ponatinib 1gilteritinib 1fludarabine phosphate 1fludarabine 1enasidenib 1blinatumomab 1asciminib 1Sensitivity and Specificity 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Idarubicin 1Gemtuzumab 1Filgrastim 1Daunorubicin 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myeloid × Daunorubicin × Clear all
NCT00129168 2008-04-01

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Kanisa Pharmaceuticals

Phase 1/2 Completed
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡